Latest News

Volastra vies for the next big synthetic lethality target

  • ApexOnco

Volastra Therapeutics Forms New Partnerships to Advance KIF18A Inhibitors in Cancer

  • The Clinical Trial Vanguard

Targeting A Multitude of CIN in Cancer Cells (Podcast)

  • The Bio Report

Lilly-Backed Volastra Enters Clinic with Amgen’s KIF18A Inhibitor

  • BioSpace

Volastra licenses Amgen molecule for chromosomally unstable cancers

  • C&EN

Armed with $60M series A and Lilly’s backing, Volastra enters clinic via Amgen cancer med

  • Fierce Biotech

Oncology specialist Volastra brings in PhI drug from Amgen, nabs $60M in Series A

  • Endpoints News

On heels of landmark approval, Bristol Myers Squibb embarks on billion-dollar oncology deal with metastatic cancer startup

  • Endpoints News